Search clinical trials for: pemetrexed cisplatin

Total 4023 results

University Hospital, Lille
University of Pennsylvania; Institut National de la Santé Et de la Recherche... and other collaborators

Completed

Intrapleural Photodynamic Therapy in a Multimodal Treatment for Patients With Malignant Pleural Mesothelioma (MesoPDT)

Malignant Pleural Mesothelioma

France
Wuhan Union Hospital, China

Unknown

Clinical Trial of Tumor Cell-derived Microparticles Packaging Chemotherapeutic Drugs to Treat Malignant Pleural Effusion

Malignant Pleural Effusion

China
Jiangsu Hansoh Pharmaceutical Co., Ltd.

Not yet recruiting

A Study of HS-10241 Combined With Almonertinib Versus Platinum-based Chemotherapy in Treatment of Advanced NSCLC With MET Amplification After Failure of EGFR-TKI Therapy

Non-Small Cell Lung Cancer
Eli Lilly and Company

Completed

A Study of Pemetrexed Plus Carboplatin, or Pemetrexed Plus Cisplatin With Radiation Therapy Followed by Pemetrexed in Patients With Inoperable Non-Small-Cell Lung Cancer

Non-Small-Cell Lung Cancer

United States, India
Targovax Oy
Theradex

Unknown

A Randomised Phase II Open-label Study With a Phase Ib Safety lead-in Cohort of ONCOS-102, an Immune-priming GM-CSF Coding Oncolytic Adenovirus, and Pemetrexed/Cisplatin in Patients With Unresectable Malignant Pleural Mesothelioma

To Determine Safety, Tolerability and Efficacy of ONCOS-102 in Combination With Chemotherapy

Spain, France
AstraZeneca

Active, not recruiting

Phase III Open Label First Line Therapy Study of MEDI 4736 (Durvalumab) With or Without Tremelimumab Versus SOC in Non Small-Cell Lung Cancer (NSCLC) (MYSTIC)

Non-Small-Cell Lung Carcinoma NSCLC

United States, Belgium, Spain, Canada, Taiwan, Thailand, Vietnam, France, Germany, Italy, Korea, Republic of, Hungary, Japan, Russian Federation, Netherlands, Australia, Switzerland
ImmunityBio, Inc.

Active, not recruiting

QUILT 2.023: A Study of N-803 in Combination With Current Standard of Care vs Standard of Care as First-Line Treatment for Patients With Stage 3 or 4 NSCLC.

Non Small Cell Lung Cancer

United States
Hutchison Medipharma Limited

Recruiting

Study on Savolitinib Combined With Osimertinib in Treatment of Advanced NSCLC With MET Amplification (SACHI)

Non-small Cell Lung Cancer

China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Active, not recruiting

A Clinical Trial of TQB2450 Injection Combined With AL2846 Capsules in Patients With Advanced Solid Tumors

Solid Tumor

China
Nevada Cancer Institute

Terminated

Phase I/II Trial of PTK787 and Pemetrexed With or Without Cisplatin for Lung Cancer

Non-Small Cell Lung Cancer and Pleural Mesothelioma

United States
GlaxoSmithKline

Completed

Study to Evaluate GSK3052230 in Combination With Paclitaxel and Carboplatin, or Docetaxel or as Single Agent in Subjects With Solid Malignancies and Deregulated Fibroblast Growth Factor (FGF) Pathway Signaling

Neoplasms

United States, Denmark, Spain, Belgium, United Kingdom, Russian Federation, Netherlands
Third Military Medical University

Unknown

Application of Detecting Circulating Tumor Cells in the Accurate Treatment of Early Stage Lung Adenocarcinoma (CTCs detection)

Treatment | Diagnoses Diseases | Lung Adenocarcinoma, Stage I | Circulating Tumor Cells

China
AstraZeneca

Completed

Assess Safety & Efficacy of Selumetinib When Given in Combination With Standard First Line Treatment for Advanced Non-small Cell Lung Cancer (SELECT-3)

Locally Advanced or Metastatic NSCL Cancer Stage IIIB IV

United Kingdom
Centre Oscar Lambret

Completed

Pemetrexed, Cisplatin, and Vitamin B12 in Treating Patients With Mesothelioma of the Chest That Cannot Be Removed by Surgery

Malignant Mesothelioma

France
Avistone Biotechnology Co., Ltd.

Not yet recruiting

Efficacy and Safety Evaluation of PLB1004 in Patients With Non-squamous NSCLC Harboring EGFR Exon 20 Insertion.

Non-Small-Cell Lung Cancer
Eli Lilly and Company

Completed

Molecular Profiling in Lung Cancer Patients

Carcinoma | Non-Small Cell Lung Cancer

Poland
Shandong Cancer Hospital and Institute

Recruiting

A Study to Evaluate the Safety of Concurrent Durvalumab With CRT Followed by Durvalumab for Chinese Unresectable Stage III NSCLC

Unresectable Stage III NSCLC

China
Innovent Biologics (Suzhou) Co. Ltd.

Recruiting

Efficacy and Safety of IBI351 in Combination With Sintilimab ± Chemotherapy in Advanced Non-squamous Non-small Cell Lung Cancer Subjects With KRAS G12C Mutation

Advanced Non-Small Cell Lung Cancer

China
University of California, Davis
Novartis Pharmaceuticals

Completed

Study of Cisplatin and Pemetrexed in Combination With Panobinostat in Solid Tumors

Solid Tumors | Non-Small Cell Lung Cancer (NSCLC)

United States
Tianjin Medical University Cancer Institute and...
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Not yet recruiting

Penpulimab-based Combination Neoadjuvant/Adjuvant Therapy for Patients With Resectable Locally Advanced Non-small Cell Lung Cancer: a Phase II Clinical Study (ALTER-L043) (ALTER-L043)

Resectable Locally Advanced Non-small Cell Lung Cancer

China
Washington University School of Medicine

Terminated

Effect of Chemotherapy and Radiation Prior to Surgery for Triple Negative Breast Cancer

Breast Cancer

United States
SciClone Pharmaceuticals

Unknown

Thymosin Alpha 1 Plus Maintenance Therapy With the Standard of Care (SoC) in Patients With Metastatic Non-Small Cell Lung Cancer (NSCLC), EGFR Wild Type

Non-Small Cell Lung Cancer

Italy
Taizhou Hanzhong biomedical co. LTD

Recruiting

HX008 Plus Chemotherapy VS Pembrolizumab Plus Chemotherapy As the First-line Treatment in Participants With Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer

Nonsquamous Non-small Cell Lung Cancer

China
Eli Lilly and Company

Completed

A Study for Patients With Head and Neck Cancer

Head and Neck Neoplasms

United States, China, Puerto Rico, Germany, Spain, Hungary, Italy, Denmark, India, Poland, Netherlands, Belgium, France, Mexico, Taiwan, Romania, Russian Federation, Korea, Republic of, South Africa, Argentina, Brazil
SCRI Development Innovations, LLC
Pfizer

Withdrawn

Lorlatinib in Combination With Chemotherapy in Participants With Metastatic Anaplastic Lymphoma Kinase Positive (ALK+) Non-small Cell Lung Cancer (NSCLC) Who Progressed on Single-agent Lorlatinib (NSCLC)

Lung Cancer | Non-small Cell Lung Cancer

United States
Allarity Therapeutics

Completed

Phase I/II Study to Evaluate the Safety and Tolerability of LiPlaCis in Patients With Advanced or Refractory Tumours (LiPlaCis)

Phase 1: Advanced or Refractory Solid Tumours | Phase 2 Part: Metastatic Breast Cancer, Prostate Cancer and Skin Cancer

Denmark
Masonic Cancer Center, University of Minnesota

Recruiting

RMT in Combination With Durvalumab + Chemo in Untreated Adenocarcinoma NSCLC. A Randomized Double Blind Phase II Trial

Lung Cancer | Adenocarcinoma of Lung

United States
Sichuan Cancer Hospital and Research Institute
Mianyang Central Hospital; Cancer Hospital of Guizhou Province

Unknown

The Optimal Intervention Time of Radiotherapy for Oligometastatic Stage IV Non-small Cell Lung Cancer（NSCLC） (OITROLC)

Oligo-metastatic Stage IV Non-small Cell Lung Cancer

China
University Health Network, Toronto

Completed

Dacomitinib Plus Radiotherapy, With and Without Cisplatin in Patients With Squamous Cell Carcinoma of the Head and Neck

Squamous Cell Carcinoma of the Head and Neck

Canada
AstraZeneca

Active, not recruiting

Study of Durvalumab+Olaparib or Durvalumab After Treatment With Durvalumab and Chemotherapy in Patients With Lung Cancer (ORION) (ORION)

Non-small Cell Lung Cancer NSCLC

United Kingdom, Belgium, United States, Korea, Republic of, Hungary, Japan, Russian Federation, Poland, Ukraine, India, Mexico, Netherlands
Patrick Joseph Loehrer Sr.

Completed

Phase II Study of Alimta (Pemetrexed) Treatment of Advanced Thymoma and Thymic Carcinoma

Thymic Carcinoma | Thymoma

United States
Guangdong Association of Clinical Trials

Not yet recruiting

Camrelizumab Combined With SRT/WBRT and Chemotherapy in Patients With Brain Metastases of Driven Gene-negative NSCLC

Non-Small-Cell Lung Cancer
Istituto Oncologico Veneto IRCCS
MSD Italia S.r.l.

Not yet recruiting

Induction Chemo+Immunotherapy in Resectable Epithelioid and Biphasic Pleural Mesothelioma (CHIMERA Study) (CHIMERA)

Pleural Mesothelioma

Italy
The Netherlands Cancer Institute
Karolinska Institutet; UMC Utrecht; Maastricht Radiation Oncology; The Christie... and other collaborators

Active, not recruiting

Adaptive Radiation Treatment for Head and Neck Cancer (ARTFORCE)

Head and Neck Cancer

Spain, Netherlands, Sweden, France, United Kingdom
The Netherlands Cancer Institute
Pfizer

Completed

Standard Chemotherapy With of Without Axitinib in Malignant Mesothelioma (N08CPA)

Malignant Pleural Mesothelioma

Netherlands
Rongjie Tao
National Natural Science Foundation of China

Unknown

Pemetrexed and Temozolomide in Treating Patients With Relapsed Primary Central Nervous System Lymphoma （PCNSL）

Central Nervous System Tumors
PrECOG, LLC.
AstraZeneca; University of Sydney; Thoracic Oncology Group Australasia (TOGA)

Active, not recruiting

DuRvalumab With chEmotherapy as First Line treAtment in Advanced Pleural Mesothelioma (DREAM3R)

Mesothelioma | Malignant Pleural Mesothelioma | Pleural Mesothelioma

United States, Australia, New Zealand
Finnish Lung Cancer Group
Roche Pharma AG

Completed

Erlotinib Treatment Beyond Progression in EGFR Mutant NSCLC

Non-small Cell Lung Cancer

Finland
Radboud University Medical Center

Completed

Platin-based Chemotherapeutics to Enhance Dendritic Cell Vaccine Efficacy in Melanoma Patients

Melanoma

Netherlands
University Medical Center Groningen
Dutch Cancer Society

Not yet recruiting

IMPT Dose Escalation for NSCLC (HyDose) (HyDose)

Carcinoma, Non-Small-Cell Lung

Netherlands
Qilu Hospital of Shandong University

Unknown

Study of Thalidomide in Treatment of Advanced Nsclc (Dream-003)

Advanced Nsclc

China
Baylor College of Medicine

Terminated

Study of Cytoreductive Surgery and Hyperthermic Intraoperative Chemotherapy With Pemetrexed and Cisplatin for MPM

Mesothelioma

United States
Eli Lilly and Company

Approved for marketing

ALIMTA (Pemetrexed) Alone or in Combination With Cisplatin for Patients With Malignant Mesothelioma.

Mesothelioma

United States, Brazil, Egypt, Saudi Arabia
Georgetown University

Terminated

Use of Pharmacogenetics to Select Erbitux or Cisplatin to Treat Head and Neck Cancer

Head and Neck Squamous Cell Cancer

United States
GlaxoSmithKline

Not yet recruiting

Evaluation of Programmed Death Ligand 1 (PDL1) Response to Treatment in Patient-derived Organoids and Immune-marker Positron Emission Tomography (PET) Scanning in Non-small Cell Lung Cancer (NSCLC)

Lung Cancer, Non-Small Cell

United Kingdom
Jiangsu HengRui Medicine Co., Ltd.

Not yet recruiting

A Study of HRS-4642 in Patients With Advanced Solid Tumors Harboring KRAS G12D Mutation

Advanced KRAS G12D Mutant Solid Tumors

China
Hangzhou ACEA Pharmaceutical Research Co., Ltd.
Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Withdrawn

A Study Comparing AC0010 and Chemotherapy in Patients With Advanced NSCLC Who Have Progressed Following Prior EGFR TKI

NSCLC

China
UNICANCER
National Cancer Institute, France

Recruiting

PD-1 Inhibitor and Chemotherapy With Concurrent Irradiation at Varied Tumour Sites in Advanced Non-small Cell Lung Cancer (NIRVANA-LUNG)

Non Small Cell Lung Cancer | Non Small Cell Lung Cancer Metastatic | Non-Small Cell Carcinoma of Lung, TNM Stage 4

France, Monaco
National Cancer Institute (NCI)

Withdrawn

AMG 102, Pemetrexed Disodium, and Cisplatin in Treating Patients With Malignant Pleural Mesothelioma

Recurrent Malignant Mesothelioma | Advanced Malignant Mesothelioma | Epithelial Mesothelioma | Sarcomatous Mesothelioma
Curis, Inc.

Completed

Phase I Study of CUDC-101 With Cisplatin and Radiation in Subjects With Head & Neck Cancer

Head and Neck Cancer

United States

Search clinical trials for: pemetrexed cisplatin

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Myanmar

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations